<DOC>
	<DOC>NCT02001389</DOC>
	<brief_summary>This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of [18F]MNI-659 [a PET tracer targeting phosphodiesterase 10 (PDE10)] by EVP-6308.</brief_summary>
	<brief_title>Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308</brief_title>
	<detailed_description />
	<criteria>â€¢ Healthy male or female volunteers, 18 to 50 years of age Clinically significant abnormalities on physical examination, medical history, ECG , vital signs, laboratory values, or unstable medical or psychiatric illness Any disorder that may interfere with drug absorption. Clinically significant allergy or sensitivity to medications Positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C antibody. Pregnant or breast feeding. History of exposure to any radiation &gt;15 mSv/year (e.g., occupational or radiation therapy) over the past year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Enzyme occupancy</keyword>
	<keyword>Positron emission tomography (PET)</keyword>
	<keyword>Phosphodiesterase 10 inhibitor</keyword>
</DOC>